Serhat Sekmek, Hatice Bolek, Omer Faruk Kuzu, Elif Sertesen Camoz, Saadet Sim, Hilal Karakaş, Murad Guliyev, Aysun Fatma Akkus, Selver Isık, Gökhan Uçar, Deniz Tural, Cagatay Arslan, Sema Sezin Goksu, Ozlem Nuray Sever, Nuri Karadurmus, Cengiz Karacin, Mehmet Ali Nahit Sendur, Emre Yekedüz, Yüksel Ürün
{"title":"nivolumab治疗转移性肾细胞癌的尿酸水平：土耳其肿瘤组肾癌联盟（TKCC）的一项研究","authors":"Serhat Sekmek, Hatice Bolek, Omer Faruk Kuzu, Elif Sertesen Camoz, Saadet Sim, Hilal Karakaş, Murad Guliyev, Aysun Fatma Akkus, Selver Isık, Gökhan Uçar, Deniz Tural, Cagatay Arslan, Sema Sezin Goksu, Ozlem Nuray Sever, Nuri Karadurmus, Cengiz Karacin, Mehmet Ali Nahit Sendur, Emre Yekedüz, Yüksel Ürün","doi":"10.1080/1750743X.2025.2527019","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>To investigate the effect of uric acid level on prognosis in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab.</p><p><strong>Materials and methods: </strong>This retrospective study utilized data from the Turkish Oncology Group Kidney Cancer Consortium (TKCC), which is a multicenter registry encompassing 13 cancer centers across Türkiye.</p><p><strong>Results and conclusions: </strong>A total of 189 patients were included in the study. The median age was 61 years in all cohort. Univariable analyses revealed longer TTF (17.87 vs. 6.57 months, <i>p</i> = 0.014) and OS (52.01 vs. 25.36, <i>p</i> = 0.032) in the uric acid-high (UAH) group than in the uric acid-low (UAL) group. In multivariable analyses, low uric acid level emerged as an independent risk factor for OS (hazard ratio (HR): 1.82, 95% confidence interval (CI): 1.09-3.05; <i>p</i> = 0.022), whereas no significant association was observed with TTF (HR: 1.24, 95% CI: 0.72-2.13; <i>p</i> = 0.431). While uric acid levels were a significant independent prognostic factor for OS, no association was found with TTF. Our findings underscore the prognostic importance of uric acid in mRCC, suggesting its potential role as a biomarker for risk stratification.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"649-655"},"PeriodicalIF":2.3000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12269686/pdf/","citationCount":"0","resultStr":"{\"title\":\"Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study.\",\"authors\":\"Serhat Sekmek, Hatice Bolek, Omer Faruk Kuzu, Elif Sertesen Camoz, Saadet Sim, Hilal Karakaş, Murad Guliyev, Aysun Fatma Akkus, Selver Isık, Gökhan Uçar, Deniz Tural, Cagatay Arslan, Sema Sezin Goksu, Ozlem Nuray Sever, Nuri Karadurmus, Cengiz Karacin, Mehmet Ali Nahit Sendur, Emre Yekedüz, Yüksel Ürün\",\"doi\":\"10.1080/1750743X.2025.2527019\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aims: </strong>To investigate the effect of uric acid level on prognosis in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab.</p><p><strong>Materials and methods: </strong>This retrospective study utilized data from the Turkish Oncology Group Kidney Cancer Consortium (TKCC), which is a multicenter registry encompassing 13 cancer centers across Türkiye.</p><p><strong>Results and conclusions: </strong>A total of 189 patients were included in the study. The median age was 61 years in all cohort. Univariable analyses revealed longer TTF (17.87 vs. 6.57 months, <i>p</i> = 0.014) and OS (52.01 vs. 25.36, <i>p</i> = 0.032) in the uric acid-high (UAH) group than in the uric acid-low (UAL) group. In multivariable analyses, low uric acid level emerged as an independent risk factor for OS (hazard ratio (HR): 1.82, 95% confidence interval (CI): 1.09-3.05; <i>p</i> = 0.022), whereas no significant association was observed with TTF (HR: 1.24, 95% CI: 0.72-2.13; <i>p</i> = 0.431). While uric acid levels were a significant independent prognostic factor for OS, no association was found with TTF. Our findings underscore the prognostic importance of uric acid in mRCC, suggesting its potential role as a biomarker for risk stratification.</p>\",\"PeriodicalId\":13328,\"journal\":{\"name\":\"Immunotherapy\",\"volume\":\" \",\"pages\":\"649-655\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12269686/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Immunotherapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/1750743X.2025.2527019\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/3 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1750743X.2025.2527019","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/3 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的：探讨尿酸水平对纳武单抗治疗的转移性肾癌（mRCC）患者预后的影响。材料和方法：本回顾性研究利用了土耳其肿瘤组织肾癌协会（TKCC）的数据，该协会是一个多中心注册机构，包括土耳其13个癌症中心。结果与结论：本研究共纳入189例患者。所有队列的中位年龄为61岁。单变量分析显示，尿酸高（UAH）组TTF （17.87 vs. 6.57个月，p = 0.014）和OS （52.01 vs. 25.36, p = 0.032）长于尿酸低（UAL）组。在多变量分析中，低尿酸水平成为OS的独立危险因素(风险比（HR）： 1.82, 95%可信区间（CI）： 1.09-3.05；p = 0.022)，而与TTF无显著相关性(HR: 1.24, 95% CI: 0.72-2.13；p = 0.431)。虽然尿酸水平是OS的重要独立预后因素，但未发现与TTF相关。我们的研究结果强调了尿酸在mRCC中的预后重要性，提示其作为风险分层的生物标志物的潜在作用。
Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study.
Aims: To investigate the effect of uric acid level on prognosis in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab.
Materials and methods: This retrospective study utilized data from the Turkish Oncology Group Kidney Cancer Consortium (TKCC), which is a multicenter registry encompassing 13 cancer centers across Türkiye.
Results and conclusions: A total of 189 patients were included in the study. The median age was 61 years in all cohort. Univariable analyses revealed longer TTF (17.87 vs. 6.57 months, p = 0.014) and OS (52.01 vs. 25.36, p = 0.032) in the uric acid-high (UAH) group than in the uric acid-low (UAL) group. In multivariable analyses, low uric acid level emerged as an independent risk factor for OS (hazard ratio (HR): 1.82, 95% confidence interval (CI): 1.09-3.05; p = 0.022), whereas no significant association was observed with TTF (HR: 1.24, 95% CI: 0.72-2.13; p = 0.431). While uric acid levels were a significant independent prognostic factor for OS, no association was found with TTF. Our findings underscore the prognostic importance of uric acid in mRCC, suggesting its potential role as a biomarker for risk stratification.
期刊介绍：
Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field.
Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
